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ABSTRACT
Meningiomas are a diverse group of tumors with a broad spectrum of histologic 
features. There are over 12 variants of meningioma, whose genetic features are 
just beginning to be described. Angiomatous meningioma is a World Health 
Organization (WHO) meningioma variant with a predominance of blood vessels. 
They  are  uncommon  and  confirming  the  histopathologic  classification  can  be 
challenging. Given a lack of biomarkers that define the angiomatous subtype and 
limited understanding of the genetic changes underlying its tumorigenesis, we 
compared the genomic characteristics of angiomatous meningioma to more common 
meningioma subtypes. While typical grade I meningiomas demonstrate monosomy 
of chromosome 22 or lack copy number aberrations, 13 of 14 cases of angiomatous 
meningioma demonstrated a distinct copy number profile – polysomies of at least 
one chromosome, but often of many, especially in chromosomes 5, 13, and 20. WHO 
grade II atypical meningiomas with angiomatous features have both polysomies and 
genetic aberrations characteristic of other atypical meningiomas. Sequencing of over 
560 cancer-relevant genes in 16 cases of angiomatous meningioma showed that these 
tumors lack common mutations found in other variants of meningioma. Our study 
demonstrates that angiomatous meningiomas have distinct genomic features that 
may be clinically useful for their diagnosis.Oncotarget 10597 www.impactjournals.com/oncotarget
INTRODUCTION
In adults, meningiomas are the most common 
primary tumor of the central nervous system [1]. These 
tumors arise from the leptomeninges covering the brain 
and the spinal cord. In the World Health Organization 
(WHO)  Classification  of  Tumours,  13  histological 
subtypes and three grades of meningiomas are defined 
by histologic criteria [1]. Genetic analyses have shown 
that meningiomas have recurrent copy number changes 
associated with histologic grade. The most common 
aberration is monosomy of chromosome 22, with resultant 
loss of the NF2 gene on 22q [2-4]. This aberration is 
frequently the only copy number change in WHO grade I 
meningiomas, with roughly 40% of grade I meningiomas 
displaying no recurrent changes [5]. WHO grade II and 
III meningiomas are associated with more complex 
karyotypes, most often demonstrating losses on 1p, 6q, 
9p, 10q, and 14q [5]. Genomic changes in meningioma 
are also highly associated with histologic subtype. While 
inactivating mutations in NF2 have been described in 30 to 
60% of sporadic meningiomas, recent studies have shown 
that non-NF2 meningiomas harbor activating mutations 
in SMO (L412F and W535L), AKT1 (E17K), and KLF4 
(K409Q), as well as inactivating mutations of TRAF7 [6, 
7]. Notably, SMO and AKT1 mutations are common in 
the meningothelial subtype, particularly in those arising 
from the base of the skull [6, 7]. Mutations in NF2 are 
especially common in the fibroblastic subtype while KLF4 
and TRAF7 are often mutated in the secretory subtype [8].
A small portion of meningiomas – approximately 
2% – is classified as the angiomatous variant [9, 10]. 
This WHO recognized subtype is characterized by a 
predominance of blood vessels interspersed with small 
meningothelial cells and foamy spider-like cells. Most 
of the vascular channels have a small- to medium-sized 
caliber  and  many  have  vessel  walls  with  significant 
thickening and hyalinization. Moderate to severe nuclear 
atypia is frequently present and this is ascribed to 
“degenerative changes” rather than being considered an 
indicator of malignant behavior. Moreover, meningiomas 
can demonstrate both angiomatous and microcystic 
features – the striking pleomorphism of the microcystic 
component potentially leading to an erroneous concern for 
aggressive behavior. Overall, angiomatous meningiomas 
do not behave aggressively [9-11]. Discriminating them 
from other brain tumors with hypervascularization (e.g., 
hemangiopericytomas and hemangioblastomas) and non-
neoplastic vascular lesions (e.g., vascular malformations) 
is important for appropriate clinical management. 
Currently, the diagnosis of an angiomatous 
meningioma is based exclusively on histologic review and 
specific molecular biomarkers supporting the diagnosis 
are not available. The molecular drivers of these tumors 
are also entirely unknown as is their genetic relationship 
to other vascular tumors as well as to other subtypes 
of meningiomas. To date, NF2 mutations have been 
described very infrequently in angiomatous meningioma, 
suggesting that the origin of angiomatous meningiomas is 
largely independent of NF2 [7, 12].
To  begin  to  define  the  molecular  profile  of 
angiomatous meningiomas, we performed high-resolution 
array comparative genomic hybridization (aCGH) on 14 
angiomatous meningiomas and exon sequencing of over 
560 cancer-relevant genes in 16 of these tumors. Our work 
shows that angiomatous meningiomas have a distinct 
genetic profile characterized by numerous chromosomal 
polysomies and an absence of mutations commonly found 
in other meningioma subtypes.
RESULTS
In 2012, the Clinical Cytogenetics Laboratory at 
the Brigham and Women’s Hospital began characterizing 
all meningioma samples that were evaluated by the 
Neuropathology Division using a high-resolution array-
based comparative genomic hybridization (aCGH) assay. 
This clinical test (Oncocopy) was performed in a CLIA-
certified laboratory setting (see Materials and Methods). 
The ability of this assay to reliably detect copy number 
changes from DNA purified from FFPE tissues relies on a 
novel DNA fragmentation simulation method (FSM) [13]. 
Since the start of aCGH testing, 10 cases with 
a histologic diagnosis of angiomatous meningioma or 
meningioma with angiomatous features were evaluated 
by aCGH (Table S1). The assay revealed that nine of 10 
tumors harbored polysomies. The whole genome profiles 
of somatic copy number alterations (SCNAs) are depicted 
in Figure 1 (blue–gain; red–loss). The nine cases with 
polysomy alterations were convexity meningiomas, while 
one case without trisomies (MG-38) originated from the 
petroclival region of the skull base. As is common with 
skull-based tumor, the MG-38 tumor sample was small 
and the limited tumor cells were admixed with normal 
dura raising the possibility that the inability to detect 
polysomies may have resulted from low tumor purity. 
We next performed aCGH analysis on four additional 
angiomatous meningioma cases that had been diagnosed 
at our hospital within the last five years and found that all 
four samples also harbored polysomies (Figure 1). In total, 
13 of 14 meningiomas displayed polysomy of at least one 
chromosome.
Of these 14 samples, 10 met WHO histopathology 
criteria for grade I meningioma. Some tumors 
demonstrated markedly hyalinized blood vessels (Figure 
2a-d) while others had smaller capillary-sized blood 
vessels (Figure 2d-f) with MG-19 demonstrating clusters 
of thick-walled blood vessels separated by regions of 
meningothelial cells (Figure 2f). Four cases met criteria 
for grade II atypical meningioma with increased mitoses 
or other features including increased cellularity, a high 
nuclear to cytoplasmic ratio, sheeting, prominent nucleoli Oncotarget 10598 www.impactjournals.com/oncotarget
Figure 1: aCGH of WHO grade I meningioma and angiomatous meningioma (WHO grade I and II). Plot of copy number 
gains (blue) and losses (red) for 14 angiomatous meningioma samples (top) and 12 non-angiomatous WHO grade I meningiomas (bottom) 
that were analyzed using 1x1M Agilent SurePrint G3 Human CGH Microarray chips containing 963,029 probes with 2.1 kb overall 
median probe spacing and a 1.8 kb probe spacing across the human genome (Oncocopy). Cases MG-19 through MG-229 were analyzed 
as clinical cases in a CLIA environment by the Center for Advanced Molecular Diagnostics (CAMD) at Brigham and Women’s Hospital, 
and MG-150 through MG-186 were analyzed as research cases, also by the CAMD. All non-angiomatous cases were analyzed for clinical 
diagnosis. Chromosome numbers are displayed horizontally (even numbers are listed at the top and odd numbers are listed at the bottom). 
Sex chromosomes were not analyzed or displayed. The segmented aCGH data was plotted using the aberration-plot function of the copy 
number and Bioconductor packages in R (limits -2,2).
Figure 2: Diversity of morphologies of WHO grade I angiomatous meningioma with polysomies. H&E stained sections 
demonstrate that while some angiomatous meningiomas have thick hyalinized blood vessels (a-c), others have a mixed profile of capillary-
sized blood vessels admixed with hyalinized blood vessels (d), or only predominantly capillary-sized vessels (e, f).Oncotarget 10599 www.impactjournals.com/oncotarget
and necrosis (Table S1; e.g. MG-229 in Figure 3). For 
all cases, the median age was 62 years old (range 42 to 
90), with six males and eight females. No cases have yet 
recurred, although the follow-up length is limited (less 
than three years for all but four of the cases). 
When  we  compared  the  copy  number  profiles 
of angiomatous meningioma to a panel of 12 grade I 
meningiomas with subtypes that are more commonly seen 
in clinical practice (one fibroblastic, five meningothelial, 
four transitional, and two secretory), the copy number 
changes observed in angiomatous tumors appeared 
unique and striking (Figure 1). Consistent with reports 
in the literature, none of the fibroblastic, meningothelial, 
transitional, or secretory grade I cases harbored any arm-
level gains and only two cases had monosomy 22 in the 
absence of other arm-level losses.
In contrast, angiomatous meningiomas had copy 
number gains across a range of different chromosomes. 
All of the 13 angiomatous cases with copy number gains 
had polysomy of chromosome 5 (Figures 1 and 4). In 
two of these cases (MG-87 and MG-186), polysomy 
of chromosome 5 was the only change detected – the 
remaining eleven cases had polysomies of at least 
four chromosomes, with one case (MG-19) showing 
wide-spread genome disruption with polysomies of 
13 chromosomes (Figure 1). After chromosome 5, the 
chromosomes most frequently gained were 20 (11 cases) 
and 6, 12, and 13 (9 cases each). Polysomy 7, 17, and 
18 were also present in many cases. Whole-arm gains of 
chromosomes 1, 2, 8, 9, 10 or 14 were not present in any 
of the cases (Figures 1 and 4). Loss of chromosome 3p 
(involving the VHL gene), which is frequently present in 
most hemangioblastoma – another highly vascular primary 
lesion of the central nervous system – was only observed 
in one angiomatous meningioma, and the pattern of other 
chromosomal aberrations in hemangioblastoma [14, 15] 
were absent in angiomatous meningioma. Hence, the copy 
number profiles of these two tumor types are distinct. 
Four of the samples of meningioma with 
angiomatous  features  (MG-116,  MG-131,  MG-162, 
MG-229) met criteria for designation as WHO grade II 
atypical meningioma (MG-229 shown in Figure 3). High 
grade meningiomas with angiomatous features have only 
been very infrequently reported [9, 10, 16]. All four of 
the samples of atypical meningioma with angiomatous 
features in our cohort had multiple polysomies and three 
of these four samples had genomic aberrations that are 
typically present in WHO grade II atypical meningioma 
[5] (Figure S1). MG-162 lacked such changes while MG-
116 demonstrated monosomy 14, MG-131 had a 47 Mb 
single copy loss of 6q22.31-6q27, and MG-229 had a 60 
Mb single copy loss of 1p36.33-1p31.3 and monosomy 14 
(Figure S1). 
To determine if established cancer genes are mutated 
in angiomatous meningioma, we sequenced all exons 
from 560 cancer associated genes (Tables S1 and S2) and 
performed amplicon sequencing of all exons from TRAF7 
and the exon encoding the KLF4 K409 amino acid residue 
that were not present in the OPv2 gene set (Table S1). 
Notably, mutations and deletions were not found in NF2 in 
Figure 3: Features of a WHO grade II atypical meningioma with angiomatous features. (a) Axial T1-weighted gadolinium-
enhanced MRI of patient MG-229 shows a 4.6 cm right frontal convexity meningioma that extends to the orbital roof, with moderate adjacent 
vasogenic edema and mild effacement of the anterior horn of the right lateral ventricle. H&E stained sections reveal (b) prominent thick- 
and thin-walled blood vessels with (c) microcystic change, (d) numerous mitoses, (e) and foci of necrosis, and (f) immunohistochemistry 
shows an elevated MIB-1 proliferative index. Scale bars and measurements are shown for each image.Oncotarget 10600 www.impactjournals.com/oncotarget
Figure 4: Frequency and significance of broad (arm-level) copy number aberrations in 14 angiomatous meningiomas 
by aCGH. (a.) Frequency (% of the 14 cases having the event) and (b.) q-value data as calculated by GISTIC 2.0 [38] from the 14 
angiomatous meningioma cases presented in Figure 1. 
Figure 5: Copy number analysis from exon sequencing data of 560 cancer genes. The frequency of gains and losses is shown 
in the upper panel. The copy number profile from each individual tumor sample is shown in the lower panel (blue – gain; red – loss).Oncotarget 10601 www.impactjournals.com/oncotarget
any of the 16 samples tested (Tables S3 and S4; 10 of these 
samples were analyzed by aCGH and six samples were 
not). Moreover, oncogenic driver mutations previously 
described in grade I meningiomas (including AKT1, SMO, 
KLF4, and PIK3CA) and inactivating mutations in TRAF7 
were not found in any angiomatous meningiomas. Also of 
note, mutations were not observed in the VHL gene, which 
is frequently mutated in hemangioblastoma [14, 15]. 
We next performed copy number analysis from 
the DNA sequencing data for the 16 angiomatous 
meningioma cases that had undergone Oncopanel exon 
sequencing (Figure 5). Using this orthogonal approach, 
we also readily identified multiple polysomies, again with 
frequent gains in chromosomes 5, 13, and 20 as well as 
chromosomes 6, 7, 12, 17, and 18 (Figure 5). Six of these 
sixteen cases (Table S1) only had Oncopanel sequencing 
performed and of these cases, one (MG-231) did not show 
chromosomal polysomies. It had an unusual clustering 
of thin-walled blood vessels that was distinct from other 
tumors diagnosed as angiomatous meningioma in our 
cohort.
Comparing the data from 10 cases that had had 
both Oncopanel sequencing and aCGH Oncocopy 
analysis demonstrated excellent concordance (Figures 
5 and 6; Table S1 and S5), indicating that the pattern of 
polysomies characteristic of angiomatous meningioma 
can  be  identified  using  exon  sequencing  data,  as  can 
the deletions characteristic of WHO grade II atypical 
meningioma (Figures 5 and 6; e.g., large deletions on 
chromosome 1p and 14 in MG-229). Notably, the only 
case (MG-38) that did not have polysomies detected by 
aCGH analysis also lacked polysomies in the analysis of 
the Oncopanel exon sequencing data (Figures 5 and 6). 
One apparent discrepant call is the lack of monosomy 22 
in MG-117_aCGH, which is present in MG-117_OPv2. 
A review of the data shows that there is monosomy 22 
at a fraction that does not meet the threshold called by 
the Nexus analysis software (Figure S2). This lesion 
did meet the threshold set in our prior analysis (Figure 
1). Overall, using aCGH Oncocopy data as the reference 
point (i.e., “gold” standard), the sensitivity for identifying 
whole-arm copy number gains from the Oncopanel data 
was 85% with a specificity of 86%, and the sensitivity for 
identifying whole-arm copy number losses was 100% with 
a specificity of 93% (Table S5). This high concordance 
was possible even though probe spacing and density is 
much lower for the Oncopanel sequencing assay (Figure 
S3). 
Figure 6: Comparison of copy number analysis from exon sequencing data and high-resolution aCGH data. Ten 
angiomatous meningiomas were characterized by both exon sequencing (OPv2) and aCGH. The plot displays the copy number changes 
from the orthogonal analytical approaches (blue - gain; red - loss). Oncotarget 10602 www.impactjournals.com/oncotarget
DISCUSSION
Meningiomas are a heterogeneous group of tumors 
–  by  both  histopathology  and  molecular  profiling. To 
date, angiomatous meningiomas have been recognized 
as a WHO grade I subtype, however, there have been no 
specific molecular aberrations ascribed to this histologic 
subclass. Our study demonstrates that angiomatous 
meningiomas are distinct from other meningiomas – 
bearing numerous chromosomal polysomies and lacking 
mutations characteristic of other meningioma subtypes. 
These polysomies can be detected using aCGH analysis, 
as is now standard in our molecular diagnostics laboratory 
using our Oncocopy assay, or by exon sequencing 
strategies using a panel of genes such as Oncopanel [17]. 
These findings can help diagnostic classification and may 
shed light on the molecular pathogenesis that underlies the 
development of these tumors.
The pattern of chromosomal alterations in 
angiomatous meningioma is strikingly different than 
other grade I meningiomas, which most commonly 
harbor monosomy 22 or no recurrent chromosomal 
changes. Typically, aneuploidy is viewed as imposing 
tremendous proteotoxic stress on cells [18, 19], which 
can be detrimental to survival, growth and proliferation 
[19-22]. As such, aneuploidy and the associated cell stress 
render cancer cells preferentially susceptible to treatments 
that target the stress phenotype of malignant cells [23-25] 
and the aneuploidy state in particular [26, 27]. Despite 
the pressure placed on cells, aneuploidy has long been 
recognized as common feature of most cancer genomes, 
particularly the genomes of aggressive tumor types. 
Recently, a cumulative analyses of aneuploidy 
across cancer genomes has shown that the distribution 
and potency of tumor suppressor genes (termed “STOP” 
genes), as well as oncogene and essential genes (termed 
“GO” genes) on chromosomes are responsible for the 
recurrent patterns of aneuploidy and copy number 
variation that are observed in cancer [28, 29]. Interestingly, 
we detected highly recurrent gains of chromosomes 5, 
13, and 20 (most frequent changes) as well as gains of 
6, 7, 12, 15, 16, 17, 18, and 19 (less frequent changes). 
Across many cancers, the chromosomes that are most 
frequently gained are 7, 20, 8, 13, 12, and 5 [28, 29]. 
Angiomatous meningiomas display gains of five of these 
six chromosomes (all but chromosome 8), suggesting that 
the net growth and proliferation signals present on these 
chromosomes outweighs the inhibitory growth signals and 
the burden of stress placed by the aneuploidy state. 
Moreover, the signal for vascular differentiation, 
development, and proliferation – a hallmark of 
angiomatous meningioma – may reside on these regions 
of chromosomal gain. Interestingly, the VEGF pathway 
has been implicated in the pathogenesis of angiomatous 
meningiomas  [30]  and  the  VEGF-A gene is located 
on chromosome 6, which is frequently gained in these 
tumors. Other genes with roles in vascular development 
and proliferation reside on chromosome 5 and include 
PDGFRB, FGFR4, and FGF10. Notably, TERT is also 
present on chromosome 5.
Mutations in the TERT promoter and increased 
TERT mRNA expression were recently reported in a 
subset of meningioma that recur and undergo malignant 
progression [31]. Conceivably, the copy number gains on 
chromosome 5 in angiomatous meningioma – which do 
not typically demonstrate aggressive clinical behavior [9, 
10] – do not elevate TERT mRNA and protein levels to 
the same level as promoter mutations do. The effects of 
elevated TERT levels on tumor progression likely also 
require other companion mutations or genomic alterations 
that are not present in angiomatous meningioma.
Despite  the  significant  aneuploidy  encountered 
in angiomatous meningiomas, these tumors do not 
generally display aggressive behavior and patients have 
very favorable prognoses [9, 10]. Indeed, the presence of 
aneuploidy is not uniformly associated with worse clinical 
outcome. For instance, genetic analysis has revealed that 
there are two distinct molecular variants of ependymomas 
of the posterior fossa [32]. One subgroup has a paucity 
of copy number aberrations and poor outcome while the 
other subgroup harbors multiple recurrent chromosome 
arm-level cytogenetic aberrations including losses of 
chromosomes 1, 2, 3, 6, 8, 10, 14q, 17q, and 22q and gains 
of 4, 5q, 7, 9, 11, 12, 15q, 18, 20, and 21q; yet, the latter is 
associated with excellent survival [32-34].
Hyperdiploidy has been previously described in 
2.4% of meningioma in a cohort of 677 meningiomas 
using spectral karyotyping techniques [35]. Ten of 15 
of these hyperdiploid cases were described as having 
microcystic features and it was mentioned that those 
specimens had numerous blood vessels suggesting that 
many of those cases may have had angiomatous features. 
The diagnosis of angiomatous meningioma was not 
discussed in that work, however, and it is unclear whether 
the five remaining hyperdiploid cases without microcystic 
features also displayed numerous blood vessels. In our 
cohort, six of 20 cases also had microcystic features. 
Taken together, both studies support a molecular overlap 
for these meningioma subtypes which frequently co-
exist. The prior work with karyotyping suggests that a 
subset of meningioma with chromosomal polysomies 
may not display angiomatous features. Further analysis 
and independent studies will be needed to assess the 
sensitivity and specificity of chromosomal polysomies in 
the diagnosis of angiomatous meningioma.
While angiomatous meningiomas are not generally 
clinically aggressive tumors, four cases in our cohort had 
atypical features suggesting that a subset of these tumors 
might have a tendency to recur. Future insights into the 
molecular genetic drivers of these tumors that build upon 
the molecular analysis presented in this work might inform 
our understanding of the pathobiology of these tumors and Oncotarget 10603 www.impactjournals.com/oncotarget
of possible new therapeutic strategies.
MATERIALS AND METHODS
Specimens and clinical characteristics
Research aCGH testing on human tumor specimens 
and analysis of clinical aCGH data was conducted 
following the approval from the Dana-Farber/Brigham 
and Women’s Cancer Center (DF/BWCC) Institutional 
Review Board. All aCGH testing was performed within 
a CLIA-certified laboratory environment in the Clinical 
Cytogenetics Laboratory/Center for Advanced Molecular 
Diagnostics (CAMD) at Brigham and Women’s 
Hospital. All tumor samples were reviewed by at least 
two neuropathologists (M.A.A. and S.S.) and were 
classified according to the World Health Organization 
(WHO) criteria of brain tumors. Fourteen angiomatous 
meningioma samples were analyzed by aCGH, of which 10 
were processed as clinical specimens and four as research 
specimens. A group of 12 WHO grade I meningioma 
including  meningothelial,  fibrous,  transitional,  and 
secretory subtypes that had undergone clinical aCGH 
testing were analyzed as a comparative group. This group 
had a similar age and gender distribution as the group of 
angiomatous meningioma. Targeted sequencing of 560 
cancer-related genes was performed on 16 angiomatous 
meningiomas and amplicon sequencing of coding exons 
from  TRAF7 and for recurrent mutation in KLF4K409Q 
was performed on 15 cases (Table S1). Ten angiomatous 
meningioma had both aCGH and sequencing analysis 
(Table S1). The MIB-1 proliferation index was taken from 
the clinical report.
aCGH using FFPE samples
To identify tumor-specific genomic copy number 
alterations, we performed Oncocopy, an array-based 
comparative genomic hybridization (aCGH) test 
using  a  stock  1x1M  Agilent  SurePrint  G3  Human 
CGH Microarray chip. A minimum of 1.3 µg of DNA, 
corresponding to approximately 10 X 5 µm standard FFPE 
sections or 6 X 1 mm punches containing at least 50% 
tumor, was obtained for each specimen. Genomic DNA 
isolated from FFPE blocks was hybridized with genomic 
DNA isolated from a commercial reference DNA sample 
representing a pool of individuals with normal karyotypes 
(Promega, Madison, WI). The array platform contains 
963,029  probes  spaced  with  a  2.1  kb  overall  median 
probe spacing and a 1.8 kb probe spacing in RefSeq genes 
across the human genome. Data analysis was performed 
according to standard settings of the CLIA laboratory. 
aCGH analysis
Raw copy number data in the form of aCGH text 
files  were  mapped  using  Homo sapiens UCSC hg18 
build. Array normalization and removal of unmapped 
probes were conducted using algorithms provided by the 
Memorial Sloan Kettering Cancer Center, Cancer Genome 
Characterization Center (Novel normalization algorithms 
and QA measure for array CGH, (http://cbio.mskcc.org/
CGCC/)
Circular Binary Segmentation (CBS) was used to 
segment  copy-number  data  from  research  aCGH  [36, 
37]. CBS was performed using Matlab (The MathWorks, 
Inc., Natick, MA) with parameters of α = 0.01, undo.
splits = none, minimum width = 5. Segmented data were 
analyzed using GISTIC 2.0 [38] to determine statistically 
significant recurrent copy number alterations (CNAs), 
after filtering germline copy number variations, using 
the following parameters: minimum segment size of 10, 
focal  versus  broad  CNA  events  defined  with  a  cutoff 
of 0.5x chromosome arm length, and gene confidence 
level of 0.99. Copy number alterations were called when 
associated with log2 copy number changes >0.2. Analysis 
of significant CNAs excluded chromosomes X and Y [38]. 
Segmented aCGH data and Oncopanel Data were plotted 
using the aberration-plot function of the copy number and 
Bioconductor packages in R [39, 40]. GISTIC CNAs were 
plotted using GraphPad Prism (GraphPad Software, San 
Diego, CA).
DNA  isolation  and  exon  sequencing  of 
angiomatous meningioma FFPE samples 
We obtained DNA from approximately 5-10 X 0.6 
mm punches (diameter 1 mm, Miltex, Plainsboro, NJ) 
from  formalin-fixed  paraffin-embedded  (FFPE)  tissue 
blocks containing at least 50% tumor using QIAamp 
DNA  FFPE  Tissue  Kit  (Qiagen,  Valencia,  CA).  The 
concentration of double-stranded DNA was quantified 
using Quant-iT™ PicoGreen® dsDNA Assay Kit (Life 
Technologies, Carlsbad, CA). Tumor samples were 
resected between 2003 and 2014. 
Exons of 560 cancer-relevant genes were sequenced 
at the Center for Cancer Genome Discovery (CCGD) at 
the  Dana-Farber  Cancer  Institute  (OncoPanel  version 
2, OPv2), using an Illumina sequencing platform. Prior 
to preparation of the library, 200 ng of double-stranded 
DNA was fragmented to approximately 250bp segments 
using Covaris sonication (LE220 Focused-ultrasonicator, 
Covaris, Woburn, MA). Fragmented DNA was purified 
using Agencourt AMPure XP beads (Beckman Coulter, 
Inc. Indianapolis, IN). A total of 50 ng of size-selected 
DNA was then ligated to sequencing adaptors with 
sample-specific barcodes (Illumina TruSeq) and quantified 
by qPCR. For exon enrichment, libraries were pooled in Oncotarget 10604 www.impactjournals.com/oncotarget
equal mass to a total of 500 ng, and exonic regions were 
captured with the SureSelect Target Enrichment system 
(Agilent Technologies, Santa Clara, CA). The capture 
pool was sequenced in one lane of the HiSeq 2500 system 
(Illumina Inc., San Diego, CA) in Rapid Run Mode.
We de-multiplexed the pooled sample reads 
and  sorted  the  data  using  Picard  tools  (http://picard.
sourceforge.net/command-line-overview.shtml). We 
aligned the reads to the reference sequence b37 edition 
from the Human Genome Reference Consortium, using 
bwa (http://bio-bwa.sourceforge.net/bwa.shtml) – 
parameters “-q 5 -l 32 -k 2 -o 1.” Duplicate reads were 
removed  using  the  Picard  tools  [41].  The  alignments 
were further refined using the GATK tool for localized 
realignment around indel sites (http://www.broadinstitute.
org/gsa/wiki/index.php/Local_realignment_around_
indels). 
Recalibration of the quality scores was also 
performed using GATK tools (http://www.broadinstitute.
org/gsa/wiki/index.php/Base_quality_score_recalibration) 
[42, 43]. The mean target coverage across all samples was 
on average 102x with 89% of all targets at 30x coverage 
or more.
Oncopanel variant analysis
Mutation analysis for single nucleotide variants 
(SNV) was performed using MuTect v1.1.4 [44] and 
annotated by Oncotator (http://www.broadinstitute.org/
oncotator/). We used the SomaticIndelDetector tool 
that is part of the GATK for indel calling. MuTect and 
SomaticIndelDetector were run in either paired mode 
using  a  matched  normal  as  the  germline  filter,  or  in 
paired mode using internal control CEPH as the normal 
for tumor samples without a match. A germline variant 
filter was applied to the tumors with no matched normals. 
Non-synonymous  variants  were  filtered  against  the 
6,500 exome release of the Exome Sequencing Project 
(ESP) database. Variants represented at >1% in either 
the African-American or European-American and not in 
COSMIC > 2x were considered to be germline. There 
were very few variants in the tumors with matched normal. 
In the tumors without matched normal mutations were 
generally 10-20 times higher. Listed in Table S2 are the 
560 sequenced genes and the 39 chromosomal breakpoints 
that were evaluated. 
Oncopanel copy number analysis
We performed copy number analysis using Nexus7.1 
(BioDiscovery Inc.) after calculating the sequencing 
coverage using PICARD. Coverages were normalized 
over GC-content using a lowest regression and a CCGD 
normal DNA (17_L_000344) as reference. CNVs were 
called using next generation sequencing (NGS) versus 
aCGH settings presented in Table S5.
Amplicon sequencing of TRAF7 and KLF4 
Targeted exon enrichment was performed to 
assess the mutational status of TRAF7 and KLF4 using a 
custom Qiagen GeneRead DNAseq panel following the 
manufacturer’s suggested protocol (Qiagen, Valencia, 
CA). Each sample was prepared and sequenced in 
duplicate  to  identify  and  eliminate  PCR  artifacts. 
Sequencing libraries were prepared using the NEBNext 
DNA Library Prep methods and barcoded with unique 
indices. Libraries were pooled in equimolar concentrations 
and sequenced on an Illumina MiSeq using150bp paired 
end reads to an average depth of approximately 4,500x. 
Data analysis was performed using the Qiagen NGS 
Data Analysis Web Portal. All alterations were manually 
inspected by Integrated Genome Viewer (IGV) (http://
www.broadinstitute.org/igv).
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